Payal Patel

Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.

M. Kris, V. Rusch, C. Azzoli, 2014, Clinical lung cancer.

Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.

A. Abernethy, S. Khozin, R. Pazdur, 2018, The oncologist.